Trial Profile

The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti CD20 chimeric antigen receptor T cell therapy Hebei Senlang Biotechnology (Primary) ; Senl 1904A (Primary) ; Cyclophosphamide; Fludarabine
Indications Haematological malignancies; Leukaemia; Lymphoma; Myeloma; Tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Hebei Senlang Biotechnology

Most Recent Events

24 Jun 2025 Planned End Date changed from 6 Dec 2024 to 6 Dec 2027.
24 Jun 2025 Planned primary completion date changed from 6 Sep 2024 to 6 Sep 2027.
24 Jun 2025 Status changed from completed to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com